Ask AI
ProCE Banner Activity

Current and Emerging Therapies for Advanced NSCLC With Uncommon EGFR and EGFR Exon 20 Insertion Mutations

Clinical Thought

Read this commentary to gain expert insights on the current and emerging treatment landscape for patients with advanced NSCLC and uncommon EGFR mutations or EGFR exon 20 insertion mutations.

Released: April 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Taiho Oncology, Inc.

Taiho Oncology, Inc.

Target Audience

This activity is intended for medical oncologists, pulmonologists, and other healthcare professionals caring for patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply clinical trial evidence to guide the personalized use of EGFR-targeted monotherapies, combinations, and antibody–drug conjugates across the EGFRm NSCLC disease continuum, including postprogression and earlier stages of disease

  • Assess and mitigate adverse events associated with novel EGFR-directed therapies using evidence-based management strategies to optimize adherence and quality of life

  • Integrate patient-specific factors—including molecular resistance patterns, prior treatment exposure, comorbidities, and preferences—into individualized treatment planning for EGFRm NSCLC

  • Evaluate the latest evidence on emerging agents and combinations for patients with EGFR Exon 20 mutation-positive NSCLC

Disclosure

Primary Author

Nicolas Girard, MD, PhD: consultant/advisor/speaker: AbbVie, Accord, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Johnson & Johnson, Lilly, Merck Sharp & Dohme, Natera, Pfizer, PharmaMar, Pierre Fabre, Regeneron, Summit.

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Blossom Hill Therapeutics, Boehringer Ingelheim, Daiichi Sankyo, Genmab, Gilead, Janssen, Lilly, Natera, Regeneron, Revolution Medicines, Summit, Taiho, Takeda, Tubulis; researcher: AbbVie, AstraZeneca, Blossom Hill Therapeutics, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Nuvalent, Spectrum, Systimmune, Takeda, Tesaro/GSK.